rsv-f subunit vaccine
Vaccineexperimental
Clinical trial activity
11 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
7
Phase 3
2
Phase 4
0
Earliest trial started Dec 1, 2010 (NCT01290419)
Timeline
Indications
Mechanism of action
- Respiratory syncytial virusImmunity, active
Respiratory syncytial virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- rsv-f subunit vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02624947 | Phase 3 | Dec 1, 2015 | Bill and Melinda Gates Foundation, Novavax |
| NCT02608502 | Phase 3 | Nov 1, 2015 | Novavax |
| NCT02593071 | Phase 2 | Oct 1, 2015 | Novavax |
| NCT02298179 | Phase 1 | Dec 19, 2014 | GlaxoSmithKline |
| NCT02296463 | Phase 1 | Nov 1, 2014 | Novavax |
| NCT02266628 | Phase 2 | Oct 1, 2014 | Novavax |
| NCT02247726 | Phase 2 | Sep 1, 2014 | Novavax |
| NCT01960686 | Phase 2 | Oct 1, 2013 | Novavax |
| NCT01709019 | Phase 1 | Oct 1, 2012 | Novavax |
| NCT01704365 | Phase 2 | Oct 1, 2012 | Novavax, PATH |
| NCT01290419 | Phase 1 | Dec 1, 2010 | ICON, Novavax |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novavax | For profit | 10 | 10 | 3 | 2010 |
| Bill and Melinda Gates Foundation | Academic/Hospital | 1 | 0 | 1 | 2015 |
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2014 |
| ICON | For profit | 1 | 0 | 1 | 2010 |
| PATH | Academic/Hospital | 1 | 0 | 1 | 2012 |
5 organizations
Page 1 / 1